SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s ...

Spyre Therapeutics Inc. SYRE shares are up on Monday following the announcement of positive results from the Phase 2 SKYLINE ...

Spyre Therapeutics hit the key target in a trial of its candidate treatment for moderate to severely active ulcerative colitis. The clinical-stage biotechnology company said Monday it achieved ...

Shares of Spyre Therapeutics jumped ahead of the opening bell after the biotechnology company hit the key target in a trial of its candidate treatment for moderate to severely active ulcerative ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

-PK/PD confirm results seen in healthy volunteer studies, with median RO >99% and saturation achieved early and sustained at week 12- WALTHAM, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Morphic ...

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...

Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...

Intestinal ultrasound (IUS) is non-invasive, cost-effective, and accurate to determine disease activity in ulcerative colitis (UC). In this study, we prospectively evaluated IUS for treatment response ...

Spyre Therapeutics (NASDAQ:SYRE) shares climbed 25% on Monday after the company reported that its investigational therapy ...